COVID-19 impact on portfolio management
Webinars: Navigating markets in uncertain times
Discover our regular webinar series exploring economic and financial data insights from Refinitiv
About this series
Our webinar series is designed to take a look at the economic weakness, market impact and effect on investments due to COVID-19, with the risks and opportunities this presents. We examine the analytical tools and data that can help manage investment decisions for portfolio managers, investment professionals and asset managers.
By accessing some of the best content sets in this industry, the webinar series is aimed at providing a fresh perspective, reinforce existing strategies or offering the insight needed to take a new direction on your portfolio asset allocations. We have independent experts from - MSCI, Fathom Consulting, Marketpsych, Clarivate Analytics, with some of our in house experts from Datastream, StarMine, ESG, I/B/E/S estimates to name a few.
July 30, 2020 | 2pm BST
How are healthcare and pharma stocks impacted by the pandemic?
Join this webinar to discover investment opportunities within the pharmaceutical industry and see who is developing a meaningful drug solution for COVID-19 as well as:
- How to find trusted analytics away from the headlines to those pharma companies holding the intellectual rights to a COVID-19 vaccine
- Get techniques to analyzing a drug pipeline for generating alpha
- The breadth and depth of gaining smart information: Clarivate Analytics and Eikon Healthcare App its value to the analyst
You are invited to watch and listen to our previous webinars on the COVID-19 pandemic; reviewing the impact across economies, markets and industries to help you navigate the extraordinary challenges today and ahead.
The Biggest Global Recession since 1930? Preparing for the Economic and Financial Impact of the Coronavirus
Analysing corporate behaviour in the context of COVID-19
Investment management solutions
With active asset managers under pressure from the popularity of passive funds and the squeeze on fees, finding alpha is hard. So whether your approach is fundamental or pure quant, our data and technology will help you.